Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

9 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Comparative oncogenomics identifies combinations of driver genes and drug targets in BRCA1-mutated breast cancer.
Annunziato S, de Ruiter JR, Henneman L, Brambillasca CS, Lutz C, Vaillant F, Ferrante F, Drenth AP, van der Burg E, Siteur B, van Gerwen B, de Bruijn R, van Miltenburg MH, Huijbers IJ, van de Ven M, Visvader JE, Lindeman GJ, Wessels LFA, Jonkers J. Annunziato S, et al. Among authors: brambillasca cs. Nat Commun. 2019 Jan 23;10(1):397. doi: 10.1038/s41467-019-08301-2. Nat Commun. 2019. PMID: 30674894 Free PMC article.
EZH2 Is Overexpressed in BRCA1-like Breast Tumors and Predictive for Sensitivity to High-Dose Platinum-Based Chemotherapy.
Puppe J, Opdam M, Schouten PC, Jóźwiak K, Lips E, Severson T, van de Ven M, Brambillasca C, Bouwman P, van Tellingen O, Bernards R, Wesseling J, Eichler C, Thangarajah F, Malter W, Pandey GK, Ozretić L, Caldas C, van Lohuizen M, Hauptmann M, Rhiem K, Hahnen E, Reinhardt HC, Büttner R, Mallmann P, Schömig-Markiefka B, Schmutzler R, Linn S, Jonkers J. Puppe J, et al. Clin Cancer Res. 2019 Jul 15;25(14):4351-4362. doi: 10.1158/1078-0432.CCR-18-4024. Epub 2019 Apr 29. Clin Cancer Res. 2019. PMID: 31036541
Combined inhibition of EZH2 and ATM is synthetic lethal in BRCA1-deficient breast cancer.
Ratz L, Brambillasca C, Bartke L, Huetzen MA, Goergens J, Leidecker O, Jachimowicz RD, van de Ven M, Proost N, Siteur B, de Korte-Grimmerink R, Bouwman P, Pulver EM, de Bruijn R, Isensee J, Hucho T, Pandey G, van Lohuizen M, Mallmann P, Reinhardt HC, Jonkers J, Puppe J. Ratz L, et al. Breast Cancer Res. 2022 Jun 17;24(1):41. doi: 10.1186/s13058-022-01534-y. Breast Cancer Res. 2022. PMID: 35715861 Free PMC article.
MYC promotes immune-suppression in triple-negative breast cancer via inhibition of interferon signaling.
Zimmerli D, Brambillasca CS, Talens F, Bhin J, Linstra R, Romanens L, Bhattacharya A, Joosten SEP, Da Silva AM, Padrao N, Wellenstein MD, Kersten K, de Boo M, Roorda M, Henneman L, de Bruijn R, Annunziato S, van der Burg E, Drenth AP, Lutz C, Endres T, van de Ven M, Eilers M, Wessels L, de Visser KE, Zwart W, Fehrmann RSN, van Vugt MATM, Jonkers J. Zimmerli D, et al. Among authors: brambillasca cs. Nat Commun. 2022 Nov 2;13(1):6579. doi: 10.1038/s41467-022-34000-6. Nat Commun. 2022. PMID: 36323660 Free PMC article.
CD26-negative and CD26-positive tissue-resident fibroblasts contribute to functionally distinct CAF subpopulations in breast cancer.
Houthuijzen JM, de Bruijn R, van der Burg E, Drenth AP, Wientjens E, Filipovic T, Bullock E, Brambillasca CS, Pulver EM, Nieuwland M, de Rink I, van Diepen F, Klarenbeek S, Kerkhoven R, Brunton VG, Scheele CLGJ, Boelens MC, Jonkers J. Houthuijzen JM, et al. Among authors: brambillasca cs. Nat Commun. 2023 Jan 12;14(1):183. doi: 10.1038/s41467-023-35793-w. Nat Commun. 2023. PMID: 36635273 Free PMC article.
MYC is a clinically significant driver of mTOR inhibitor resistance in breast cancer.
Bhin J, Yemelyanenko J, Chao X, Klarenbeek S, Opdam M, Malka Y, Hoekman L, Kruger D, Bleijerveld O, Brambillasca CS, Sprengers J, Siteur B, Annunziato S, van Haren MJ, Martin NI, van de Ven M, Peters D, Agami R, Linn SC, Boven E, Altelaar M, Jonkers J, Zingg D, Wessels LFA. Bhin J, et al. Among authors: brambillasca cs. J Exp Med. 2023 Nov 6;220(11):e20211743. doi: 10.1084/jem.20211743. Epub 2023 Aug 29. J Exp Med. 2023. PMID: 37642941 Free PMC article.
Galectin-3 in Prostate Cancer Stem-Like Cells Is Immunosuppressive and Drives Early Metastasis.
Caputo S, Grioni M, Brambillasca CS, Monno A, Brevi A, Freschi M, Piras IS, Elia AR, Pieri V, Baccega T, Lombardo A, Galli R, Briganti A, Doglioni C, Jachetti E, Bellone M. Caputo S, et al. Among authors: brambillasca cs. Front Immunol. 2020 Sep 10;11:1820. doi: 10.3389/fimmu.2020.01820. eCollection 2020. Front Immunol. 2020. PMID: 33013832 Free PMC article.